RxDoctor Payments Data

Steven Billet, MD

Geriatric Medicine · Eldersburg, MDNPI 1477596039

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Pfizer at 26.3% of the total. Reporting peaked in 2020 at $260 and has fallen 92.7% since, to $19 in 2025.

$498in general payments, 2019–2025

Across 31 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$131
  • Amgen$98
  • AbbVie$80
  • Lilly USA, LLC$45
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$36
  • Novo Nordisk$27
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$44990%
  • Education$4910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$498 in reported general payments places this provider in the 65th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$183,510
Medicare patients
197
Services billed
3,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$99,838
OzempicSemaglutide27$46,748
OxycontinOxycodone Hcl19$34,491
XareltoRivaroxaban11$18,233
LinzessLinaclotide12$16,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,271
Aimovig AutoinjectorErenumab-Aooe12$8,589
SynthroidLevothyroxine Sodium61$5,533
Rosuvastatin Calcium180$4,128
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen75$2,768
Oxycodone Hcl91$2,712
Calcitriol88$1,962
Alprazolam135$1,650
Potassium Chloride72$1,565
Atorvastatin Calcium93$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Levoxyl$131$100,792100 claims
Novo NordiskOzempic$27$46,74827 claims
AbbVieLinzess, Synthroid$80$22,49273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Eldersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →